A fixed dose combination formulation of rifaximin or a pharmaceutically acceptable salt thereof and lactulose is provided. The formulation is used for the prevention, treatment, or maintaining remission of HE reducing the recurrence of HE episodes reducing the recurrence of HE episodes in a patient refractory or non-responsive to rifaximin or lactulose monotherapy or reducing the frequency of hospital visit.